DRG 683 Overview

DRG 683 covers inpatient stays for renal failure with at least one Complication or Comorbidity. It encompasses acute and chronic kidney failure presentations when an associated condition increases resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity elevates relative payment compared with renal failure cases without comorbidities, reflecting higher expected hospital resource consumption. Accurate clinical coding of renal failure and related comorbid conditions affects reimbursement and case mix classification.

Commercial payer rates for DRG 683 span roughly from $8.5K to $18K across the payers listed, with individual payer medians ranging from $8.5K (BCBS) up to $16K (Aetna). The widest spread between payer medians and maximums appears among Anthem and Aetna payers, with maximums reported up to $34K and $25K respectively. See the table and chart below for payer-specific distributions and percentile detail.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 683. These values reflect nationwide Medicare payment and charge averages for the covered cases in 2023.

• Acute renal support and early intervention trials: Studies examining timing, modality, and protocols for acute kidney replacement therapies (including intensive hemodialysis/CRRT initiation thresholds, anticoagulation strategies, and fluid management) in hospitalized patients with acute renal failure complicated by comorbidities. These trials enroll patients with new or worsening renal failure during an inpatient stay—often critically ill or hemodynamically unstable—and test whether earlier or protocolized interventions reduce progression to sustained renal replacement therapy or multiorgan failure. This research is directly relevant to inpatient clinicians and payers because optimal acute management may shorten length of stay, lower ICU resource use, and reduce downstream costs associated with chronic dialysis dependence.
• Comparative effectiveness studies of bundled inpatient care pathways and complication prevention: Trials or pragmatic comparative studies that evaluate care bundles (e.g., nephrotoxin stewardship, contrast-sparing imaging protocols, optimized hemodynamic management, and standardized electrolyte/acid–base protocols) versus usual care for patients admitted with renal failure and at-risk comorbid conditions. These studies target heterogeneous hospital populations with renal dysfunction and common CCs (sepsis, heart failure, liver disease) to determine which multidisciplinary pathways reduce in-hospital complications, readmissions for renal or cardiovascular issues, and rates of progression to chronic kidney disease. Findings inform hospitals and payers about which care coordination and quality improvement investments most effectively reduce complications and total cost of care for this high-risk DRG.
• Post-discharge outcomes and transitional care interventions: Research focused on post-discharge follow-up models, such as early nephrology clinic visits, pharmacist-led medication reconciliation, home lab monitoring, or telehealth monitoring for patients discharged after an inpatient renal failure episode to prevent readmission and monitor recovery of renal function. These cohort studies or randomized trials enroll survivors of inpatient renal failure—often older adults with multimorbidity and polypharmacy—and measure outcomes like renal recovery, 30- and 90-day readmissions, and progression to chronic dialysis. Payers and healthcare systems use this evidence to design transitional care programs that reduce costly readmissions and long-term dialysis initiation, aligning clinical outcomes with reimbursement and value-based care goals.